Tag: UK

University of Oxford is currently studying ivermectin as a possible therapy against COVID-19 in the UK

Frank

UK – Researchers from the university of Oxford under the PRINCIPLE study project are currently giving Ivermectin, a widely used anti-parasitic drug, to over-50s with COVID symptoms to see if it can keep them out of hospital. PRINCIPLE is a nationwide clinical study from the University of Oxford in collaboration with the British government trying to find COVID-19 treatments for recovery at home. The project is currently having any willing citizen over-50s with an underlying health condition or experiencing breathlessness and have had COVID symptoms for up to 14 days…

Read More

Enhanze drug delivery technology brings ViiV Healthcare and Halozyme into a collaboration

Frank

UK – ViiV Healthcare, a global specialist HIV that is majorly owned by GlaxoSmithKline plc have announced a global collaboration and license agreement that gives exclusive access to Halozyme’s ENHANZE drug delivery technology, recombinant human hyaluronidase PH20 enzyme (rHuPH20), for specific targets used in the treatment and prevention of HIV. The license gives ViiV exclusive use of Halozyme’s proprietary rHuPH20 technology for four, specific HIV medicine targets that will expand opportunities for development of nearly all of ViiV’s pipeline assets. Under the terms of the agreement, ViiV Healthcare will make…

Read More

A boost for the NHS as the UK government announces a US$50.3m investment on AI research

Frank

UK – The UK government has announced a hefty £36bn funding boost for artificial intelligence (AI) research technologies in a bid to help the National Health System (NHS) transform the quality of healthcare. Funding will go toward the winners of the second wave of the NHS AI Lab’s AI in Health and Care Award. The AI award package also includes funding to support the research, development and testing of early phase, of promising ideas which could be used by the NHS in the future. Since the first round of the…

Read More

Rich nations pledge 1 billion vaccine doses to developing countries, as they plan to expand manufacturing

Frank

UK – The UK has pledged to donate least 100 million surplus coronavirus vaccine doses within the next year, including 5 million beginning in the coming weeks. The announcement was made prior to the G-7 summit, whose leaders are expected to commit to provide 1 billion doses in efforts to end the pandemic by 2022. At the Summit, world leaders are expected to announce they will provide at least 1 billion coronavirus vaccine doses to the world through dose sharing and financing and set out a plan to expand vaccine…

Read More

USD 3.6 million worth of illegally sold medicines and devices seized in UK as part of global crackdown

Frank

UK – Over 3 million medicines and medical devices valued at over £9 million have been seized by UK officers as part of a global operation tackling the illegal online sale of medicines and medical devices. In the UK, 113,000 illegally operating websites were also removed or had their URLs blocked. Eight search warrants were executed, with 7 criminals arrested. Under Operation Pangea, over 100 countries joined forces to seize non-compliant medical products and also to identify and remove thousands of illegally operating websites and URLs offering medicines and devices.…

Read More

Biosphere tenant Iksuda Therapeutics raises $47m to reinforce Antibody Drug Conjugate pipeline

Frank

UK – UK-headquartered Iksuda Therapeutics has announced the closing of a $47m (£34m) financing round, with the funds to be used to support the advancement of its lead antibody drug conjugate (ADC) assets. This includes the company’s lead pre-clinical ADC candidate IKS03, a potentially ‘best-in-class’ CD19-targeted asset for B-cell cancers. Iksuda will use the funds to support the progression of IKS03 into first-in-human Phase clinical trials, and will also be used to fast-track its earlier-stage programs. Currently, the company’s drug development pipeline is focused on the improved safety and efficacy…

Read More